about
Oncolytic Viruses: Therapeutics With an Identity CrisisClinical development of gene therapy: results and lessons from recent successesCancer immunotherapy: the beginning of the end of cancer?High-throughput screening to enhance oncolytic virus immunotherapyViruses as nanomedicine for cancerSpotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodesPrime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyDeletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesRecent advances in genetic modification of adenovirus vectors for cancer treatmentSingle vs. combination immunotherapeutic strategies for glioma.Gene Therapy 2017: Progress and Future Directions.Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.First oncolytic virus approved for melanoma immunotherapy.CD8(+) T-cell Immune Evasion Enables Oncolytic Virus ImmunotherapyGenetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancerPhase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Design of virus-based nanomaterials for medicine, biotechnology, and energy.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model.11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cells with Enhanced Synergistic Activity.Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatmentOncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.Viral cancer therapies: are they ready for combination with other immunotherapies?Targeting Melanoma with Cancer-Killing Viruses.Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines.Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.State of play and clinical prospects of antibody gene transfer.Convection-Enhanced Delivery.Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes VirusesEmerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
P2860
Q26741020-3611C2A6-29AE-4489-91B8-0DEAFB04DC81Q26743393-AD0E0F67-C968-4CFD-9D65-53964838B5B9Q26752277-4377D6BB-3562-4A94-A4AA-2B7516C7311AQ26823674-82436832-5D7C-40B3-AA82-4488C8752215Q27690636-AFFCB7A7-983E-4EAC-9879-CC4563EDF0C9Q28077949-C2E1FCC6-07EC-49C9-8B02-F1A0A1372457Q33551626-5865335A-665F-4C98-A93C-9FD6FBADC6B5Q33625843-FB23866A-E675-4FCD-B18B-03DFA09B9846Q33635033-2A77E0D8-7845-4F76-BF26-AF31085B0F58Q33679505-060AABFF-067D-4032-9483-0A909FFA7EACQ33738828-55F63EE1-1D27-4FD1-AF8C-1581517B6E24Q33746041-B10628EB-3B79-4251-AA03-3DE24416A125Q33891559-FD7581AC-BC5F-4C76-903E-7FEC198683F1Q33899522-59FD9372-46F3-4133-BC49-94268862786EQ34552791-478B2894-7F4A-4B74-9876-6338E3619B42Q36597333-1C55C080-0952-4994-A3CA-AD15B6791721Q36753953-ADEE977F-8BC2-4DC0-B128-F585C36E8D8FQ37069810-C951E740-7CF8-49F0-B6DC-5FDB8D4BD8C7Q37225501-90142F8E-C1E3-44BB-BDC0-BD3A0202CA27Q37256174-67D4D9E1-F9B2-4D44-9033-0C6703F6C053Q37346447-0F627B15-D936-43F0-B81F-12EB8214EFC7Q37417271-D9BF5864-53C1-40FD-BE1A-90FB92A0EF83Q37502453-59D03672-6AC2-4E90-B8AB-E9A28E0EA8CDQ37667771-CF0428C0-3658-4363-9D4E-478E86E127C5Q37702075-C439E669-DF7B-441D-9A0A-CAA0377C0494Q37709496-8B643062-7646-49BC-B660-509925548E70Q37736296-8FD5432A-0F11-457E-95EF-791885C119BCQ38643300-EEFD94B8-5934-4F14-BDAE-DE5447999391Q38645128-1A3ADD63-22B7-4479-9B38-31FFC6F3F546Q38645375-81DC18EB-F638-4EAC-8EBF-33526DC0C6F8Q38647011-EA452B77-F0F6-486D-B1B8-095C7C6CAD9DQ38676416-F48CB5FC-AC77-4770-A2EF-328F0512B808Q38695916-AD37A447-177C-4F84-9D1E-68718A2AB4A1Q38714964-0A986FF6-A55E-4704-BEBF-FFAD45B41A7EQ38719858-C1AB75FD-BE0E-41F4-8B20-995B376A8E72Q38737706-04C64422-EB39-4680-B24D-C131B96CD7C4Q38744447-DD901737-4285-4999-8714-4B8B728E0696Q38781322-ED4095AF-B3CA-4708-9BD3-352738F1E415Q38795324-8CE27BED-14F9-4925-A74A-BE100AEF6A85Q38796338-840F6002-FE3A-4545-9E86-067D067E96D2
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Oncolytic viruses: a new class of immunotherapy drugs.
@en
type
label
Oncolytic viruses: a new class of immunotherapy drugs.
@en
prefLabel
Oncolytic viruses: a new class of immunotherapy drugs.
@en
P2860
P356
P1476
Oncolytic viruses: a new class of immunotherapy drugs.
@en
P2093
Frederick J Kohlhapp
Howard L Kaufman
P2860
P2888
P304
P356
10.1038/NRD4663
P50
P577
2015-09-01T00:00:00Z
P5875
P6179
1026486185